Neutralizing GDF-15 in muscle-invasive bladder cancer (MIBC): A neoadjuvant immunotherapy trial of visugromab (CTL-002) in combination with the anti-PD1 antibody nivolumab (GDFather-Neo).

Authors

Andrea Necchi

Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, Italy

Andrea Necchi , Roberto Iacovelli , Massimo Di Maio , Paolo Gontero , Petra Fettes , Kathrin Klar , Frank Hermann , Eugen Leo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2020 Gastrointestinal Cancers Symposium

bookmark_border

Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair deficient (dMMR) GI cancers.

First Author: Thierry Andre

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Preliminary safety, efficacy, and pharmacokinetics (PK) results of KN046 (bispecific anti-PD-L1/CTLA4) from a first-in-human study in subjects with advanced solid tumors.

First Author: Jermaine Coward

insert_chart_outlined

Poster

2024 ASCO Breakthrough

bookmark_border

Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.

First Author: Panpan Zhang

insert_chart_outlined

Poster

2024 ASCO Annual Meeting

bookmark_border

INSIGHT-005: A new stratum of the explorative, open-labeled, phase I INSIGHT study to evaluate the feasibility and safety, as well as preliminary efficacy, of subcutaneous injections with IMP321 (eftilagimod alpha) in combination with PD-L1 inhibitor (avelumab) for metastatic or unresectable locally advanced urothelial carcinoma (UC)—IKF-s614.

First Author: Igor Tsaur